CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may h...
Phase 3
London, United Kingdom and 39 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
London, United Kingdom and 73 other locations
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...
Phase 3
London, London, City Of, United Kingdom and 78 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
London, London, City Of, United Kingdom and 179 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
London, Greater London, United Kingdom and 83 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
London, United Kingdom and 103 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
London, United Kingdom and 234 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
London, United Kingdom and 558 other locations
The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for t...
Phase 2
London, United Kingdom and 10 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
London, United Kingdom and 487 other locations
Clinical trials
Research sites
Resources
Legal